Neonatal phenobarbital and phenytoin binding profiles

Area of Science:

• Pharmacology
• Neonatal Medicine
• Drug Metabolism

Background:

• Phenobarbital and phenytoin are commonly used anticonvulsants.
• Neonatal drug disposition differs significantly from adults due to physiological immaturity.
• Understanding drug binding is crucial for optimizing neonatal therapy.

Purpose of the Study:

• To determine the binding profiles of phenobarbital and phenytoin in neonates.
• To investigate factors influencing drug binding in this population.
• To assess the predictive value of in vitro binding for in vivo drug concentrations.

Main Methods:

• Drug binding assays were performed on 27 neonates.
• In vitro binding was correlated with total protein and albumin levels.
• In vivo binding was assessed at 0.5 hours and correlated with clinical parameters.
• The influence of concomitant medications, bilirubin, free fatty acids, and pH was evaluated.

Main Results:

• Both phenobarbital and phenytoin showed decreased binding in neonates compared to older subjects.
• In vitro binding correlated significantly with total protein and albumin.
• In vivo binding correlated with birth weight and gestational age.
• Phenobarbital binding decreased with co-administration of other drugs, but phenytoin did not.
• Bilirubin, free fatty acids, and pH did not significantly affect binding.
• In vitro binding accurately predicted in vivo free fractions and plasma concentrations.

Conclusions:

• Neonatal drug binding is reduced and influenced by specific factors like protein and gestational age.
• In vitro binding assays are reliable predictors of in vivo drug behavior in neonates.
• These findings aid in optimizing phenobarbital and phenytoin dosing in newborns.